Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aegerion Pharmaceuticals Announces Interim Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile
Webcast of Company-Sponsored Symposium to Review Clinical Data Scheduled for June 16th 2009, 12:30-2:00 pm ET at the ISA (International Symposium on Atherosclerosis) in Boston, MA
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data
Results Confirm Preliminary Data and Demonstrate Strong Efficacy, Safety and Tolerability Profile of Lomitapide
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile
Results Will Be Presented Today At AHA Conference in Orlando, Florida
View HTML
Toggle Summary Aegerion Pharmaceuticals Appoints Marc Beer as CEO
Aegerion Pharmaceuticals Appoints Marc Beer as CEO BRIDGEWATER, NJ– September 13, 2010 – Aegerion Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, today announced that Marc Beer has joined the
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Pricing of Initial Public Offering
BRIDGEWATER, N.J., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share, before underwriting discounts and commissions.
View HTML
Toggle Summary Underwriters Exercise Over-Allotment Option for Aegerion Pharmaceuticals' Initial Public Offering
BRIDGEWATER, N.J., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common
View HTML
Toggle Summary Aegerion Pharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
BRIDGEWATER, N.J., Nov. 5, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the Lazard
View HTML
Toggle Summary Aegerion Pharmaceuticals to Announce Third-Quarter 2010 Financial Results on Tuesday, November 30
BRIDGEWATER, N.J., Nov. 23, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced that the Company will host a conference call and
View HTML
Toggle Summary Aegerion Pharmaceuticals Announces Third-Quarter 2010 Financial Results
BRIDGEWATER, N.J., Nov. 30, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced its financial results and business highlights
View HTML
Toggle Summary Aegerion Pharmaceuticals to Present at the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
BRIDGEWATER, N.J., Dec. 1, 2010 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced today that it will participate in the 5 th Annual
View HTML